文献速递血栓与止血

抗凝治疗中异常子宫出血的管理:患者与临床医生视角

Management of abnormal uterine bleeding on anticoagulation: the patient-clinician perspective.
PubMed 文献 · J Thromb Haemost · 2024-04-19

本文综述抗凝治疗中异常子宫出血(含月经过多)的发生率、并发症及管理策略,并讨论患者体验,包括月经过多对生活质量的影响以及静脉血栓栓塞诊断和抗凝开始时停用激素治疗的影响,最后指出研究与临床中与患者体验相关的特定空白。

要点

  • 月经过多在育龄女性中极为常见,抗凝治疗可加重或导致异常子宫出血。
  • 抗凝相关月经过多影响治疗策略和患者体验,但关注相对较少。
  • 综述总结抗凝人群中月经过多的发生率、并发症及管理策略。

核心结论

  • 抗凝相关月经过多对治疗策略和患者体验的影响关注相对较少,本文总结其发生率、并发症和管理策略并指出患者体验相关的研究与临床空白。

研究设计与样本

  • 综述,总结抗凝治疗个体中月经过多的发生率、并发症及管理策略,并讨论患者体验。

主要发现

  • 出血是抗凝治疗公认的副作用,抗凝用于治疗所有年龄段的静脉血栓栓塞(VTE),包括女性,其常因激素治疗和/或妊娠并发症而发生VTE。
  • 月经过多在育龄女性中极为常见。
  • 抗凝相关月经过多影响治疗策略和患者体验,但关注相对较少。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bleeding is a well-recognized side effect of anticoagulant therapy, which is used to treat venous thromboembolism (VTE) in individuals of all ages, including those of female sex, who commonly experience VTE as a complication of hormonal therapies and/or pregnancy. Heavy menstrual bleeding (HMB) is also extremely common in reproductive-aged individuals of female sex. Despite these overlapping situations, relatively little attention has been paid to the impact of anticoagulant-associated HMB on treatment strategies and the patient experience. In this review, we summarize incidence and complications of HMB in anticoagulated individuals as well as management strategies for HMB in this population. We also address the patient experience, including the impact of HMB on quality of life and the impact of discontinuing hormonal therapies at the time of VTE diagnosis and anticoagulant initiation. We conclude by highlighting specific gaps related to the patient experience of anticoagulant-associated HMB in both the research and clinical settings.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Samuelson Bannow BT. Management of abnormal uterine bleeding on anticoagulation: the patient-clinician perspective. J Thromb Haemost. 2024. PMID: 38642705. doi:10.1016/j.jtha.2024.04.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。